0.022
0.00 (0.00%)
| Previous Close | 0.022 |
| Open | 0.022 |
| Volume | 200,000 |
| Avg. Volume (3M) | 1,318,808 |
| Market Cap | 37,196,720 |
| Price / Sales | 27.54 |
| Price / Book | 21.48 |
| 52 Weeks Range | |
| Earnings Date | 28 Feb 2025 |
| Operating Margin (TTM) | -228.29% |
| Diluted EPS (TTM) | 0.000 |
| Quarterly Revenue Growth (YOY) | 720.70% |
| Total Debt/Equity (MRQ) | 101.04% |
| Current Ratio (MRQ) | 0.350 |
| Operating Cash Flow (TTM) | -2.31 M |
| Levered Free Cash Flow (TTM) | -3.25 M |
| Return on Assets (TTM) | -74.42% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (SG) | Mixed | Mixed |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Biolidics | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.63 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| BIOLIDICS | 37 M | - | - | 21.48 |
| CORDLIFE | 69 M | - | - | 0.620 |
| HC SURGICAL | 45 M | 5.36% | 14.00 | 2.62 |
| ASIAMEDIC | 14 M | - | - | 0.950 |
| CLEARBRIDGE | 7 M | - | - | 0.470 |
|
Biolidics Ltd is engaged in technology development, technology transfer, marketing, sale and distribution of biomedical technology, life, and medicine science-related products and services, and investment holding. The company's business segments are; Cancer, Infectious diseases, Laboratory services, and Corporate. The majority of the company's revenue is generated from the laboratory services segment which involves the business, operation, and provision of laboratory services to customers. Its operations are spread across Singapore, Japan, China, Europe, the United States, Hong Kong, the Philippines, Indonesia, and Others. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 60.17% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Zhu (Hua) | 03 Oct 2024 | 505,500,000 (29.90%) |
| Wu (Kun Wei) | 03 Oct 2024 | 168,008,400 (9.94%) |
| Yuan (Zhi Jun) | 03 Oct 2024 | 148,391,600 (8.78%) |
| Zhou (Chao) | 03 Oct 2024 | 83,000,000 (4.91%) |
| Enterprise Singapore | 18 Mar 2024 | 25,880,800 (1.53%) |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 17 Jun 2025 | Announcement | REPL::Extraordinary/ Special General Meeting::Voluntary |
| 26 May 2025 | Announcement | Extraordinary/ Special General Meeting::Voluntary |
| 21 May 2025 | Announcement | General Announcement::MINUTES OF ANNUAL GENERAL MEETING HELD ON 29 April 2025 |
| 17 May 2025 | Announcement | General Announcement::Proposed shares issuance, change of company name, diversification, ratification of & entry into IPTs |
| 29 Apr 2025 | Announcement | REPL::Annual General Meeting::Voluntary |
| 14 Apr 2025 | Announcement | Annual Reports and Related Documents:: |
| 14 Apr 2025 | Announcement | Annual General Meeting::Voluntary |
| 10 Apr 2025 | Announcement | Financial Statements and Related Announcement::Discrepancies between unaudited and audited accounts |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |